Guard Therapeutics International AB (DE:5LH0)
FRANKFURT:5LH0
Want to see DE:5LH0 full AI Analyst Report?
5LH0 Stock Chart & Stats
€0.04
€0.06(3.57%)
At close: 4:00 PM EST
€0.04
€0.06(3.57%)
Day’s Range― - ―
52-Week Range€0.01 - €2.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.51M
Enterprise Value-€15.95M
Total Cash (Recent Filing)€40.99M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-56.58
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding20,167,631
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially reduces refinancing pressure and interest obligations for a pre-revenue biotech. This durable structural strength lengthens optionality: management can prioritize clinical and regulatory milestones over near-term debt servicing, lowering bankruptcy risk between financings.
A1M Platform And Renal FocusA focused platform around A1M targeting kidney diseases is a durable strategic asset. Platform technologies can generate multiple candidates, support licensing or partnerships, and concentrate R&D expertise in a high-unmet-need niche, improving long-term commercial and partnering optionality.
Cash Flow Aligns With Accounting LossesOperating cash flow that tracks reported losses indicates limited aggressive non-cash accounting and clearer spend visibility. For investors and partners this improves forecasting of runway and financing needs, a durable positive for planning clinical programs and evaluating funding timing.
Bears Say
No RevenueAbsence of any revenue means the company lacks commercial validation and must rely entirely on external funding. Over a multi-quarter horizon this increases dilution risk and creates binary dependency on clinical success or partner deals to ever achieve sustainable cash generation.
Sustained Heavy Cash BurnLarge, persistent negative operating cash flows are structurally problematic for a small biotech: they rapidly deplete resources, force repeated financing rounds, and increase dilution. Over 2–6 months this dynamic elevates funding risk and could constrain development programs.
Eroding Equity And Asset BaseSharp declines in equity and assets reflect sustained cash consumption and shrinking financial cushion. This materially reduces negotiating leverage with partners, limits flexibility to self-fund trials, and raises the likelihood of dilutive financings or asset sales to sustain operations.
5LH0 FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was €0.01 and its highest was €2.27 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is €2.51M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 13, 2026. The company reported -€0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.029.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -€0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in DE:5LH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―